Last reviewed · How we verify
Felbinac Trometamol Injection
Felbinac trometamol is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation.
Felbinac trometamol is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation. Used for Acute pain and inflammation, Postoperative pain, Musculoskeletal pain conditions.
At a glance
| Generic name | Felbinac Trometamol Injection |
|---|---|
| Also known as | 4-Biphenylacetic Acid Trishydroxymettiylaminometnane, 4-Biphenylacetic Acid |
| Sponsor | Shijiazhuang Yiling Pharmaceutical Co. Ltd |
| Drug class | Non-steroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase (COX-1 and COX-2) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Felbinac is a propionic acid derivative NSAID that works by inhibiting both COX-1 and COX-2 enzymes, thereby decreasing the production of pro-inflammatory prostaglandins. The trometamol salt formulation is designed to enhance solubility and bioavailability for parenteral administration. This mechanism provides analgesic, anti-inflammatory, and antipyretic effects.
Approved indications
- Acute pain and inflammation
- Postoperative pain
- Musculoskeletal pain conditions
Common side effects
- Gastrointestinal irritation
- Dyspepsia
- Nausea
- Injection site reactions
- Headache
Key clinical trials
- A Phase Ⅲ Clinical Study Trial of Felbinac Trometamol Injection in China (PHASE3)
- A Phase # Clinical Study Trial of Felbinac Trometamol Injection in China (PHASE3)
- A Phase Ⅱ Clinical Study Trial of Felbinac Trometamol Injection in China (PHASE2)
- A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China (PHASE1)
- A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: